Clinical significance of adiponectin expression in colon cancer patients

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 2, 2014, Pages 347-353

  Canhoroz, Mustafa ^a   Kanat, Ozkan ^a   Saraydaroglu, Ozlem ^b   Buluc, Emine ^b   Avci, Nilufer ^a   Cubukcu, Erdem ^a   Olmez, Omer ^a   Manavoglu, Osman ^a  

^a FIRAT UNIVERSITY   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Adiponectin; colon cancer; obesity related malignancies

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CANCER STAGING; COLON TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR INVASION;

ADIPONECTIN; ADULT; AGED; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905698696     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.136634     Document Type: Article

References (59)

1. Bianchini F, Kaaks R, Vainio H. Overweight, obesity and cancer risk. Lancet Oncol 2002;3:565-74.
2. Lin S, Thomas TC, Storlien LH, Huang XF. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes 2000;24:639-46.
3. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: A metaanalysis of prospective studies. Am J Clin Nutr 2007;86:556-65.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
5. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004;5:153-65.
6. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: A meta-analysis of 31 studies with 70 000 events. Cancer Epidemiol Biomarkers Prev 2007;16:2533-47.
7. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
8. Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Wada R, Mitsushima T, et al. The effect of body weight reduction on the incidence of colorectal adenoma. Am J Gastroenterol 2008;103:2061-7.
9. Zaniboni A, Labianca R, Marsoni S, Torri V, Mosconi P, Grilli R, et al. GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma-long term results and evaluation of the indicators of health-related quality of life. Cancer 1998;82:2135-44.
10. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44.
11. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899-906.
12. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22:3395-407.
13. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22:1797-806.
14. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19.
15. André T, Boni C, Navarro M, Hickish T, Topham C, Bonetti A, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-16.
16. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
17. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6.
18. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-63.
19. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in obesity-related diseases. Horm Res 2003;3:56-9.
20. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutr 2007;86:858S-66.
21. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: A systematic review. Br J Cancer 2006;94:1221-5.
22. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;9:5699-704.
23. Mantzoros CS, Williams CJ, Manson JE, Meigs JB, Hu FB. Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. Am J Clin Nutr 2006;84:328-35.
24. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237:109-14.
25. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece. J Clin Endocrinol Metab 2003;88:993-7.
26. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-3.
27. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005;65:1168-72.
28. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340:1158-66.
29. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: A case control study. Cancer Epidemiol. Biomarkers Prev 2007;16:308-13.
30. Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res 2005;11:3642-6.
31. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 2005;97:1688-94.
32. Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: A link between obesity and cancer. Expert Opin Investig Drugs 2006;15:917-31.
33. Korner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: In vitro and in vivo studies. J Clin Endocrinol Metab 2007;92:1041-8.
34. Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, et al. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer 2008;15:289-99.
35. Barresi V, Tuccari G, Barresi G. Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density, Pathology 2009;41:533-8.
36. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. On behalf of the ESMO Guidelines Working Group Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21:70-7.
37. NCCN Clinical Practice Gudelines in Oncology Colon Cancer, Version 3 2011; Available from: http://www.nccn.org/professionals/physician-gls/pdf/colon. pdf [Last accessed on 08/29/12]
38. D. J. Sargent for the Adjuvant Colon Cancer Endpoints (ACCENT) Group. Time-dependent patterns of failure and treatment benefit from adjuvant therapy for resectable colon cancer: Lessons from the 20,800-patient (pt) ACCENT dataset. J Clin Oncol 2007;25:4008.
39. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials. J Clin Oncol 2005;23:8664-70.
40. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-7.
41. Enker WE, Havenga K, Polyak T, Thaler H, Cranor M. Abdomino perineal resection via total mesorectal excision and autonomic nerve preservation for low rectal cancer. World J Surg 1997;21:215-20.
42. Bui L, Rempel E, Reeson D, Simunovic M. Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 2006;93:439-45.
43. American Cancer Society: Cancer Facts and Figures. Atlanta, Ga: American Cancer Society, 2007.
44. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/ document/globalfactsandfigures 2007rev2p.pdf [Last accessed on 2012]
45. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003;10:65-71.
46. Dousoy G. Kolon Kanserinin Patolojik Özellikleri. Alemdarolu K, Akçal T, Bura D (Editörler). Kolon Rektum ve Anal Bölge Hastalklar. stanbul: Türk Kolon ve Rektum Cerrahi Dernei; 2003.s. 413-20.
47. Wang HS, Lin JK, Mou CY, Lin TC, Chen WS, Jiang JK, et al. Long-term prognosis of patient with obstructing carcinoma of the right colon. Am J Surg 2004;187:497-500.
48. Rault A, Collet D, Sa Cunha A, Larroude D, Ndobo'epoy F, Masson B. Surgical management of obstructed colonic cancer. Ann Chirr 2005;130:331-5.
49. Alcobendas F, Jorba R, Poves I, Busquets J, Engel A, Jaurrieta E. Perforated colonic cancer. Evolution and prognosis. Rev Esp Enferm Dig 2000;92:326-33.
50. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognosis determinants and models of prognosis in Dukes' B colon cancer. Gut 2002;51:6-7.
51. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Mover VA. Lymph node evaluation and survival after curative resection of colon cancer: Systematic review. J Natl Cancer Inst 2007;99:414-5.
52. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006;17:145-56.
53. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: A review of the evidence. J Nutr 2001;131:3109-20.
54. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723-32.
55. Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept 2006;134:105-13.
56. Arditi JD, Venihaki M, Karalis K.P., Chrousos GP. Antiproliferative effect of adiponectin onMCF7breast cancer cells: A potential hormonal link between obesity and cancer. Horm Metab Res 2007;39:9-13.
57. Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005;26:69-76.
58. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2006;345:271-9.
59. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006;66:11462-70.